humanized monoclonal anti-FGFR1 antibody OM-RCA-01

Biologic

humanized monoclonal anti-FGFR1 antibody OM-RCA-01 is one of 31 biologic programs targeting Growth. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Aricept

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Growth

NCT07292168

Clinical

Trials by Indication[1]

Growth1 trial

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Recruiting·KKidney Cancer Research Bureau·Phase 1/2·NCT07292168·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for humanized monoclonal anti-FGFR1 antibody OM-RCA-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — humanized monoclonal anti-FGFR1 antibody OM-RCA-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for humanized monoclonal anti-FGFR1 antibody OM-RCA-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kidney Cancer Research Bureau company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: KKidney Cancer Research Bureau

humanized monoclonal anti-FGFR1 antibody OM-RCA-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Growth1 trial

References

Drug Info

Quick Facts

Related News